Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 27 Apr 2017 |
| Zealand announces amendments to its Articles of Association following the granting of warrants | 18 Apr 2017 |
| Zealand increases its share capital as a consequence of exercise of employee warrants | 13 Apr 2017 |
| Zealand grants new warrants under employee warrant program | 6 Apr 2017 |
| Passing of Zealand's Annual General Meeting in 2017 | 5 Apr 2017 |